Is Unicycive Therapeutics, Inc. (UNCY) a Buy, Sell, or Hold?
NASDAQ : UNCY
Unicycive Therapeutics, Inc. — Insider Trades
$5.39 USD
$0.39 (7.8%)
- Volume
- 1.5M
- Average Volume
- 1.22M
- Market Capitalization
- $143.91M
- P/E Ratio
- -3.22
- Dividend Yield
- 0.00%
- Price Target
- $22.00
- Year High
- $8.74
- Year Low
- $3.71
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.81
Insider Activity Summary (Last 12 Months)
Insiders Buying
14
Insiders Selling
3
Amount of Insider Selling
$6580.21
UNCY Insider Buying/Selling by Quarter
UNCY Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Kenkare-Mitra Sara | director | 2026-05-14 | A-Award | 0 | 2026-07-28 |
| Laumas Sandeep | director | 2026-05-14 | A-Award | 0 | 2026-07-28 |
| Gupta Shalabh K. | director, officer: CEO | 2026-05-14 | A-Award | 0 | 2026-05-21 |
| Kenkare-Mitra Sara | director | 2026-05-14 | A-Award | 0 | 2026-05-21 |
| Kenkare-Mitra Sara | director | 2026-05-14 | A-Award | 0 | 2026-05-21 |
| Jermasek Douglas | officer: EVP, Corporate Strategy | 2026-05-14 | A-Award | 0 | 2026-05-20 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2026-05-14 | A-Award | 0 | 2026-05-20 |
| Townsend John | officer: CFO | 2026-05-14 | A-Award | 0 | 2026-05-20 |
| Laumas Sandeep | director | 2026-05-14 | A-Award | 0 | 2026-05-18 |
| Laumas Sandeep | director | 2026-05-14 | A-Award | 0 | 2026-05-18 |
| Aggarwal Gaurav | director | 2025-08-25 | C-Conversion | 0 | 2025-08-26 |
| Aggarwal Gaurav | director | 2025-08-25 | D-Return | 4.9 | 2025-08-26 |
| Aggarwal Gaurav | director | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Laumas Sandeep | director | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Kenkare-Mitra Sara | director | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Gupta Shalabh K. | director, officer: CEO | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Townsend John | officer: Chief Financial Officer | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2025-07-28 | A-Award | 4.71 | 2025-07-30 |
| Aggarwal Gaurav | director | 2025-02-18 | C-Conversion | 0 | 2025-02-19 |
| Aggarwal Gaurav | director | 2025-02-18 | D-Return | 0.49 | 2025-02-19 |
| Aggarwal Gaurav | director | 2024-10-09 | C-Conversion | 1000 | 2024-10-10 |
| Aggarwal Gaurav | director | 2024-10-09 | D-Return | 0.49 | 2024-10-10 |
| Townsend John | officer: Chief Financial Officer | 2024-08-12 | A-Award | 0.34 | 2024-08-14 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2024-08-12 | A-Award | 0.34 | 2024-08-14 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2024-08-12 | A-Award | 0.34 | 2024-08-14 |
| Gupta Shalabh K. | director, officer: CEO | 2024-08-12 | A-Award | 0.34 | 2024-08-14 |
| Townsend John | officer: Chief Financial Officer | 2024-04-15 | A-Award | 1.14 | 2024-04-17 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2024-04-15 | A-Award | 1.14 | 2024-04-17 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2024-04-15 | A-Award | 1.14 | 2024-04-17 |
| Gupta Shalabh K. | director, 10 percent owner, officer: CEO | 2024-04-15 | A-Award | 1.14 | 2024-04-17 |
| Laumas Sandeep | director | 2023-09-05 | A-Award | 0.76 | 2023-09-07 |
| Kenkare-Mitra Sara | director | 2023-09-05 | A-Award | 0.76 | 2023-09-07 |
| Ryan John L | director | 2023-09-05 | A-Award | 0.76 | 2023-09-07 |
| Aggarwal Gaurav | director | 2023-09-05 | A-Award | 0.76 | 2023-09-07 |
| Kenkare-Mitra Sara | director: | 2023-09-05 | 0 | 2023-09-07 | |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-08-28 | A-Award | 0.75 | 2023-08-30 |
| Gupta Shalabh K. | director, officer: CEO | 2023-08-28 | A-Award | 0.75 | 2023-08-30 |
| Townsend John | officer: Chief Financial Officer | 2023-08-28 | A-Award | 0.75 | 2023-08-30 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-08-28 | A-Award | 0.75 | 2023-08-30 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0.7411 | 2023-07-13 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0 | 2023-07-13 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0.539 | 2023-07-13 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0.5929 | 2023-07-13 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0 | 2023-07-13 |
| Aggarwal Gaurav | director | 2023-07-11 | C-Conversion | 0.49 | 2023-07-13 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-07-11 | M-Exempt | 0.74 | 2023-07-13 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-07-11 | M-Exempt | 0.54 | 2023-07-13 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-07-11 | M-Exempt | 0.59 | 2023-07-13 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-07-11 | M-Exempt | 0.74 | 2023-07-13 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-07-11 | M-Exempt | 0.54 | 2023-07-13 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-07-11 | M-Exempt | 0.59 | 2023-07-13 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Gupta Shalabh K. | director, officer: CEO | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Gupta Shalabh K. | director, officer: CEO | 2023-07-11 | M-Exempt | 0.74 | 2023-07-13 |
| Gupta Shalabh K. | director, officer: CEO | 2023-07-11 | M-Exempt | 0.54 | 2023-07-13 |
| Gupta Shalabh K. | director, officer: CEO | 2023-07-11 | M-Exempt | 0.59 | 2023-07-13 |
| Gupta Shalabh K. | director, officer: CEO | 2023-07-11 | M-Exempt | 0.49 | 2023-07-13 |
| Schiller Brigitte | director: | 2022-07-15 | 0 | 2023-04-18 | |
| Aggarwal Gaurav | director | 2023-03-08 | A-Award | 0.4933 | 2023-03-09 |
| Gupta Shalabh K. | director, officer: CEO | 2023-03-08 | A-Award | 0.4933 | 2023-03-09 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2023-03-08 | A-Award | 0.4933 | 2023-03-09 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2023-03-08 | A-Award | 0.4933 | 2023-03-09 |
| Aggarwal Gaurav | director: | 2023-03-08 | 0 | 2023-03-08 | |
| Townsend John | officer: Chief Financial Officer | 2022-11-21 | A-Award | 0 | 2022-11-23 |
| Jermasek Douglas | officer: EVP of Corporate Strategy | 2022-11-21 | A-Award | 0 | 2022-11-23 |
| Gupta Shalabh K. | officer: CEO | 2022-11-21 | A-Award | 0 | 2022-11-23 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2022-11-21 | A-Award | 0 | 2022-11-23 |
| Jermasek Douglas | director | 2022-11-18 | 2.56 | 2022-11-21 | |
| Jermasek Douglas | director | 2022-11-18 | 0 | 2022-11-21 | |
| Schiller Brigitte | director: | 2022-07-15 | M-Exempt | 0 | 2022-08-30 |
| Schiller Brigitte | director: | 2022-05-16 | P-Purchase | 0.825 | 2022-05-17 |
| Gupta Shalabh K. | director, officer: CEO | 2021-07-15 | A-Award | 5 | 2021-07-26 |
| Gupta Pramod | officer: EVP, Pharmaceuticals and BD | 2021-07-15 | A-Award | 5 | 2021-07-26 |
| Townsend John | officer: Chief Financial Officer | 2021-07-15 | A-Award | 5 | 2021-07-26 |
| Ryan John L | director | 2021-07-12 | 0 | 2021-07-12 | |
| Ryan John L | director | 2021-07-12 | 0.01 | 2021-07-12 | |
| Gupta Shalabh K. | director, officer: CEO & President | 2021-07-12 | 0 | 2021-07-12 | |
| Gupta Shalabh K. | director, officer: CEO & President | 2021-07-12 | 0 | 2021-07-12 | |
| Gupta Shalabh K. | director, officer: CEO & President | 2021-07-12 | 0 | 2021-07-12 | |
| Gupta Shalabh K. | director, officer: CEO & President | 2021-07-12 | 0 | 2021-07-12 | |
| Gupta Shalabh K. | director, officer: CEO & President | 2021-07-12 | 0.01 | 2021-07-12 | |
| Schiller Brigitte | director: | 2021-07-12 | 0 | 2021-07-12 | |
| Laumas Sandeep | director | 2021-07-12 | 0 | 2021-07-12 | |
| Laumas Sandeep | director | 2021-07-12 | 0 | 2021-07-12 | |
| Laumas Sandeep | director | 2021-07-12 | 0.01 | 2021-07-12 | |
| Gupta Pramod | officer: EVP, Pharma and Business Ops | 2021-07-12 | 3.27 | 2021-07-12 | |
| Gupta Pramod | officer: EVP, Pharma and Business Ops | 2021-07-12 | 7.01 | 2021-07-12 | |
| Townsend John | officer: Chief Financial Officer | 2021-07-12 | 7.01 | 2021-07-12 |